We next asked whether critical immune mechanisms underlying the core features of 7HP349’s effect on CTLA-4 checkpoint blockade antitumor response in our preclinical model were associated with a specific treatment outcome for anti–CTLA-4 therapy in patients with metastatic melanoma. The gene discussed is CTLA4; the disease is metastatic melanoma.